Reja Mishal, Patel Roohi, Pioppo Lauren, Tawadros Augustine, Bhurwal Abhishek, Marino Daniel, Rustgi Vinod
Departments of Internal Medicine.
Gastroenterology.
J Clin Gastroenterol. 2021;55(5):433-438. doi: 10.1097/MCG.0000000000001389.
We aimed to investigate the mortality and hospital utilization outcomes of hospitalized nonalcoholic steatohepatitis (NASH) patients with and without kidney failure in a nationwide cohort.
NASH is a common medical condition associated with significant morbidity and mortality. A paucity of data exists regarding the impact of kidney failure (defined as acute and chronic kidney failure) on outcomes of NASH hospitalizations.
We conducted a retrospective cohort study using the 2016 Nationwide Inpatient Sample dataset of adult patients hospitalized for NASH, stratified for the presence of renal failure. The primary outcome was inpatient mortality, predictors were analyzed using multivariate logistic regression. Secondary outcomes were the length of stay and mean total hospitalization charges.
The overall sample included 7,135,090 patients. Among 6855 patients admitted for NASH, 598 or 8.7% had comorbid kidney failure. After multivariate regression analysis, NASH patients with renal failure had increased in-hospital mortality [odds ratio=28.72, 95% confidence interval (CI): 8.99-91.73], length of stay (β=3.02, 95% CI: 2.54-3.5), total hospital charges (β=$37,045, 95% CI: $31,756.18-$42,335.62). Positive predictors of mortality in the renal failure group were Charlson Comorbidity Index ≥3 [adjusted odds ratio (aOR)=3.46, 95% CI: 1.04-11.51], variceal bleeding (aOR=3.02, 95% CI: 1.06-8.61), and hepatic encephalopathy (aOR=26.38, 95% CI: 1.29-540.56). Predictors of decreased mortality were Medicaid (aOR=0.047, 95% CI: 0.28-0.79) and private insurance (aOR=0.56, 95% CI: 0.38-0.83).
The prevalence of renal failure in NASH hospitalizations is associated with markedly increased mortality, hospital costs, and length of stay. As a result, clinicians should be vigilant in treating kidney failure in this population.
我们旨在调查全国队列中伴有和不伴有肾衰竭的住院非酒精性脂肪性肝炎(NASH)患者的死亡率和医院利用结果。
NASH是一种常见的医学病症,与显著的发病率和死亡率相关。关于肾衰竭(定义为急性和慢性肾衰竭)对NASH住院患者结局的影响,现有数据较少。
我们使用2016年全国住院患者样本数据集对因NASH住院的成年患者进行了一项回顾性队列研究,根据是否存在肾衰竭进行分层。主要结局是住院死亡率,使用多因素逻辑回归分析预测因素。次要结局是住院时间和平均总住院费用。
总体样本包括7135090名患者。在6855名因NASH入院的患者中,598名(8.7%)患有合并肾衰竭。经过多因素回归分析,伴有肾衰竭的NASH患者住院死亡率增加[比值比=28.72,95%置信区间(CI):8.99 - 91.73],住院时间延长(β = 3.02,95% CI:2.54 - 3.5),总住院费用增加(β = 37045美元,95% CI:31756.18美元 - 42335.62美元)。肾衰竭组死亡率的阳性预测因素包括查尔森合并症指数≥3[调整后比值比(aOR)= 3.46,95% CI:1.04 - 11.51]、静脉曲张出血(aOR = 3.02,95% CI:1.06 - 8.61)和肝性脑病(aOR = 26.38,95% CI:1.29 - 540.56)。死亡率降低的预测因素包括医疗补助(aOR = 0.047,95% CI:0.28 - 0.79)和私人保险(aOR = 0.56,95% CI:0.38 - 0.83)。
NASH住院患者中肾衰竭的患病率与死亡率、医院成本和住院时间显著增加相关。因此,临床医生在治疗该人群的肾衰竭时应保持警惕。